Get the Stockscreener App
8.69
3.58%
0.30
After Hours:
8.69
Novavax Inc stock is traded at $8.69, with a volume of 2.95M.
It is up +3.58% in the last 24 hours and down -15.10% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$8.39
Open:
$8.38
24h Volume:
2.95M
Relative Volume:
0.59
Market Cap:
$1.42B
Revenue:
$1.12B
Net Income/Loss:
$440.30M
P/E Ratio:
3.6505
EPS:
2.3805
Net Cash Flow:
$-251.02M
1W Performance:
+3.21%
1M Performance:
-15.10%
6M Performance:
-2.47%
1Y Performance:
+35.99%
1-Day Range:
$8.38
$8.7861
1-Week Range:
$7.99
$8.7861
52-Week Range:
$5.80
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.69 | 1.37B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Discipline and Rules-Based Execution in NVAX Response - Stock Traders Daily
Novavax Inc stock (US6707721049): Is its vaccine pipeline strong enough to unlock new upside? - AD HOC NEWS
SHAH CAPITAL MANAGEMENT Increases Stake in Novavax Inc - GuruFocus
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Inc stock (US6707721049): Is its vaccine pivot strong enough to unlock new upside? - AD HOC NEWS
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
Synlogic and Novavax Face Off in Financial Analysis - National Today
Novavax, Inc. Revenue Breakdown – BSESOF:NVV1 - TradingView — Track All Markets
Why Novavax (NVAX) Is Up 5.5% After Activist Pressure Meets New R&D Leadership And What's Next - Yahoo Finance
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
US CDC delays publishing report showing COVID vaccine benefits, WaPo reports - Reuters
B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating - marketscreener.com
Novavax (NVAX) Receives a Sell from Bank of America Securities - The Globe and Mail
Shah Capital Pushes for Changes at Novavax (NVAX) - GuruFocus
Why is NVAX stock surging today? - MSN
Shah Capital Blasts Novavax Strategy In New Letter To Board - Citeline News & Insights
Shah Capital's Plan to Vote Against Novavax Board Nominees | PharmExec - Pharmaceutical Executive
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees - Pharmaceutical Executive
Investor calls for Novavax to slash costs, cut board as vaccine sales disappoint - The Business Journals
Shah Capital intends to vote against Novavax's board nominees, executive compensation - Reuters
Activist investor revives campaign to overhaul Novavax board - BioPharma Dive
Novavax Faces Shareholder Revolt As Shah Capital Criticizes StrategyNovavax (NASDAQ:NVAX) - Benzinga
3 Reasons NVAX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Novavax rises as Shah Capital calls for changes (NVAX:NASDAQ) - Seeking Alpha
Assessing Novavax (NVAX) Valuation After Renewed Focus On Covid And Malaria Vaccine Deals - Yahoo Finance
Novavax stock surges as activist pushes for board changes By Investing.com - Investing.com Canada
Why Is NVAX Stock Surging Today? - Stocktwits
Shah Capital (NVAX) discloses 9.11% Novavax stake and plans votes against board - Stock Titan
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Is Novavax (NVAX) A Potential Opportunity After Recent Share Price Weakness - Yahoo Finance
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX) - MarketBeat
Levels Update: Is Novavax Inc benefiting from interest rate changes2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Novavax, Inc. (NVAX) stock price, news, quote and history - Yahoo Finance UK
Behavioral Patterns of NVAX and Institutional Flows - Stock Traders Daily
Novavax Inc stock: Biotech innovator or fading COVID play? - AD HOC NEWS
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Shares Down 5.4%Should You Sell? - MarketBeat
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Investors heavily search Novavax, Inc. (NVAX): Here is what you need to know - MSN
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax (XTER:NVV1) PB Ratio : (As of Mar. 31, 2026) - GuruFocus
New Novavax R&D Leader Raises Questions On Valuation Gap And Outlook - Yahoo Finance
Shah Capital Management Purchases 2,747,000 Shares of Novavax, Inc. $NVAX - MarketBeat
Novavax names Robert Walker as R&D head By Investing.com - Investing.com South Africa
Novavax Stock Crosses 200-Day Moving Average - nationaltoday.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):